


## OSMI-2

|                           |  |       |          |
|---------------------------|--|-------|----------|
| <b>Cat. No.:</b>          | HY-135784  |       |          |
| <b>CAS No.:</b>           | 2260542-60-5   |       |          |
| <b>Molecular Formula:</b> | C <sub>26</sub> H <sub>25</sub> N <sub>3</sub> O <sub>7</sub> S <sub>2</sub> |       |          |
| <b>Molecular Weight:</b>  | 555.62   |       |          |
| <b>Target:</b>            | Acyltransferase  |       |          |
| <b>Pathway:</b>           | Metabolic Enzyme/Protease  |       |          |
| <b>Storage:</b>           | Powder   | -20°C | 3 years  |
|                           |  | 4°C   | 2 years  |
|                           | In solvent   | -80°C | 6 months |
|                           |  | -20°C | 1 month  |



### SOLVENT & SOLUBILITY

|   |   |                          |              |           |            |
|---|---|--------------------------|--------------|-----------|------------|
| <b>In Vitro</b>   | DMSO : 100 mg/mL (179.98 mM; Need ultrasonic)   |                          |              |           |            |
|   |   | Solvent<br>Concentration | Mass<br>1 mg | 5 mg      | 10 mg      |
|   | <b>Preparing Stock Solutions</b>  | 1 mM                     | 1.7998 mL    | 8.9990 mL | 17.9979 mL |
|   |   | 5 mM                     | 0.3600 mL    | 1.7998 mL | 3.5996 mL  |
| 10 mM   |   | 0.1800 mL                | 0.8999 mL    | 1.7998 mL |            |
| Please refer to the solubility information to select the appropriate solvent. |   |                          |              |           |            |
| <b>In Vivo</b>  | <ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline<br/>Solubility: 2.5 mg/mL (4.50 mM); Clear solution; Need ultrasonic</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil<br/>Solubility: 2.5 mg/mL (4.50 mM); Clear solution; Need ultrasonic</li> </ol> |                          |              |           |            |

### BIOLOGICAL ACTIVITY

|                                     |  |
|-------------------------------------|--|
| <b>Description</b>                  | OSMI-2 (Compound 1b) is a cell-permeable O-linked N-acetylglucosamine transferase (OGT) inhibitor. Cells contain a large nuclear pool of partially spliced OGT transcript, and OSMI-2 increases detained intron splicing in cells <sup>[1]</sup> .   |
| <b>IC<sub>50</sub> &amp; Target</b> | O-linked N-acetylglucosamine transferase (OGT) <sup>[1]</sup>  |
| <b>In Vitro</b>                     | OSMI-2 (Compound 1b; 20-50 μM; 4-24 hours; HCT116 cells) treatment reduces O-GlcNAc levels at short treatment times (<8h). However, O-GlcNAc levels begins to recover at longer treatment times with OSMI-2 <sup>[1]</sup> . A decrease in HCF-1 cleavage products and the appearance of uncleaved HCF-1 in cells treated with OSMI-2 (Compound 1b) is observed. Because OGT knockdown is known to decrease cell proliferation, the effects of OSMI-2 on cell growth in culture over 96h is also monitored. Although there is no evidence of apoptosis, the reduced growth of cells over time is observed, consistent with |

---

the knockdown results<sup>[1]</sup>.

A time course performed with 20  $\mu$ M OSMI-2 (Compound 1b) shows reciprocal changes in the abundance of OGT and OGA, with a particularly large increase in OGT; this may explain the recovery in O-GlcNAc levels with OSMI-2. At 24h where O-GlcNAc levels fully recovered<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis<sup>[1]</sup>

|                  |                                    |
|------------------|------------------------------------|
| Cell Line:       | HCT116 cells                       |
| Concentration:   | 20 $\mu$ M, 40 $\mu$ M, 50 $\mu$ M |
| Incubation Time: | 4 hours, 24 hours                  |
| Result:          | Reduced O-GlcNAc levels.           |

---

## REFERENCES

[1]. Martin SES, et al. Structure-Based Evolution of Low Nanomolar O-GlcNAc Transferase Inhibitors. J Am Chem Soc. 2018 Oct 24;140(42):13542-13545.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA